Bladder Cancer, Breast Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Head & Neck Cancer, Intestinal Cancer, Liver Cancer, Lung Adenocarcinoma, Lung Cancer (Non-Small Cell), Lung Cancer (NSCLC), Melanoma (Skin Cancer), Ovarian Cancer, Pancreas Cancer, Metastatic, Pancreas Carcinoma, Prostate Cancer, Renal Cancer, Stomach (Gastric) Cancer
Conditions
Brief summary
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.
Detailed description
This study aims to assess the anti-tumour activity, safety, and interactions of single-agent SL-28 as an anti-cancer treatment in patients with a diverse array of solid tumours. Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with advanced solid tumor, including head and neck cancer, small-cell lung cancer, non-small cell lung cancer; mesothelioma; oesophageal cancer, gastric cancer, liver cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, prostate cancer, ovarian cancer, endometrial cancer, breast cancer or skin cancer (melanoma) that is locally advanced, metastatic or unable to be surgically removed. Patients will also be assessed by a study doctor to ensure that they are well enough to participate in the trial before they will be offered enrolment into the study. Study details All participants who choose to enroll in this study will receive 12 weeks of SL-28 treatment, administered on a 5-days-on, 2-days-off schedule. The first group of participants to receive SL-28 will be monitored for 12 weeks before a second group may be administered a higher dose of SL-28. Up to three cohorts will be enrolled to determine the highest safe and effective dose that does not cause severe side effects in patients. It is hoped this study will show that SL-28 is safe to deliver to patients with solid tumour cancers, and determine the highest dose of SL-28 that cancer patients can safely receive.
Interventions
BIOLOGICALSL-28
Doses administered: 3×10\^7 cells/injection, once daily, 5 days per week, 12 weeks. Mode of administration: intravenous push
Sponsors
Second Life Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a Phase 1/2 open-label study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of SL-28, an allogeneic, non human leukocyte antigen (HLA)-matched, modified T -cell-based treatment for advanced and unresectable solid tumours. The study will be conducted in 4 parts: * Part 1: Phase 1a dose escalation as a 3+3 design, with a single dose on Day 1 followed by daily dosing from Day 8 * Part 2: Phase 1b dose expansion at the maximum tolerated dose (MTD) * Part 3: Phase 2a dose expansion in 3 tumour types * Part 4: Phase 2a dose expansion in the tumour type showing the highest efficacy to SL-28
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability to provide written informed consent prior to any study-related procedures and to understand the nature, purpose, and potential risks of the study * Adult males and females ≥18 years of age at screening * Life expectancy of at least 3 months * Histologically or cytologically confirmed unresectable advanced solid tumor (recurrent, metastatic, or locally advanced) * Disease refractory to, intolerant of, or refusal of standard therapies, including immunotherapy and molecular/biomarker-directed treatments, as determined by the Principal Investigator (PI) or delegate * Eligible tumor types include: * Head and neck squamous cell carcinoma * Thoracic malignancies (small-cell lung cancer, non-small cell lung cancer, esophageal cancer) * Gastrointestinal malignancies (gastric, liver, colorectal, pancreatic adenocarcinoma) * Genitourinary malignancies (bladder, renal cell, prostate cancer) * Gynecologic malignancies (ovarian, endometrial cancer) * Breast cancer and melanoma * Evaluable disease per RECIST v1.1 * ECOG performance status 0-1 (or up to 2 at PI discretion) * Adequate organ function, defined as: * Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for liver metastases or Gilbert's syndrome) * AST, ALT, alkaline phosphatase ≤2.5 × ULN (≤5 × ULN if liver metastases, at PI discretion) * Creatinine clearance ≥50 mL/min (Cockcroft-Gault) or eGFR ≥50 mL/min (CKD-EPI) * Absolute neutrophil count ≥1,000/mm³ * Platelet count ≥100,000/mm³ * Hemoglobin ≥90 g/L without transfusion within 2 weeks * Prothrombin time and aPTT ≤1.5 × ULN (or stable INR if on anticoagulation) Female patients: -Non-childbearing potential (surgically sterile or postmenopausal), or of childbearing potential with negative pregnancy tests and agreement to effective contraception through 90 days post-dose Male patients: * Agreement not to donate sperm for 90 days post-dose * Agreement to use adequate contraception as applicable * Suitable venous access for blood sampling * Willingness and ability to comply with study procedures and protocol requirements
Exclusion criteria
* Ongoing toxicities ≥ Grade 2 per NCI CTCAE v5.0 (except alopecia, fatigue, sensory neuropathy, or adequately treated endocrine deficiencies) * NYHA Class III or IV heart disease, myocardial infarction within 6 months, unstable arrhythmia, or ischemia on ECG * QTcF \>470 ms (females) or \>450 ms (males) * Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy * Requirement for systemic corticosteroids or other immunosuppressive therapy that cannot be discontinued ≥14 days prior to dosing * Prior therapies within restricted timeframes: * Immune checkpoint inhibitors or biologics within 28 days * Antineoplastic therapies, surgery, radiotherapy, or radiopharmaceuticals within 21 days * Unapproved investigational drugs within 5 half-lives * Nitrosoureas or mitomycin C within 6 weeks * Concurrent malignancy within 5 years, except specified low-risk cancers * Pregnancy or breastfeeding * Known HIV, hepatitis B (HBsAg positive), or hepatitis C infection * Inability or unwillingness to comply with protocol procedures * History of anaphylaxis or significant allergy interfering with participation * Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, neurologic, psychiatric, or immunologic disease within 6 months * Conditions affecting drug absorption, distribution, metabolism, or excretion * Receipt of live vaccines within 28 days prior to screening * Participation in another investigational study within 30 days prior to screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-emergent adverse events | 12 weeks | Treatment-emergent adverse events will be assessed and graded by the investigator according to the CTCAE v5 |
| To evaluate the safety and tolerability of SL-28 by determining the incidence of dose-limiting toxicitieswithin the first 28 days after infusion. | 12 weeks | Assessment of dose limiting toxicities assessed by the occurrence of treatment-emergent adverse events(TEAEs) graded by the Investigator per the National Cancer Institute Common Terminology Criteria forAdverse Events, version 5.0. |
| Change from baseline in ECG QT interval | 12 weeks | Electrocardiograms will be recorded using a 12-lead ECG machine, and the QT interval (milliseconds) will be evaluated and summarized as change from baseline. |
| Change from baseline in vital signs | 12 weeks | Vital signs including systolic blood pressure (mmHg) and diastolic blood pressure (mmHg)will be measured using standard clinical equipment and summarized as change from baseline. |
| Number of participants with dose-limiting toxicities (DLTs) | 12 weeks | Dose-limiting toxicities will be assessed during the DLT evaluation period as defined in the protocol. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) per RECIST 1.1 | 12 weeks | Objective response rate will be defined as the proportion of participants achieving a complete response (CR) or partial response (PR) according to RECIST version 1.1, as assessed by CT or MRI imaging. |
| Objective Response Rate (ORR) per iRECIST | 12 weeks | Objective Response Rate (ORR) per iRECIST |
| Disease Control Rate (DCR) per RECIST 1.1 | 12 weeks | Disease control rate will be defined as the proportion of participants achieving CR, PR, or stable disease (SD) according to RECIST version 1.1. |
Countries
Australia
Contacts
CONTACTGeorge Tetz, MD, PhD
Outcome results
None listed